News Gilead's twice-yearly PrEP drug is cleared by FDA Gilead has FDA approval for a twice-yearly PrEP drug, but could proposed cuts to US funding for HIV prevention programmes hinder its take-up?
News Has mRNA delivered a breakthrough in quest for HIV cure? A new way to deliver mRNA to T cells could allow HIV that is hiding away to be exposed and targeted with antiretroviral therapies, say scientists.
News UK's HIV response is 'failing women' Women are being overlooked in the UK's HIV response and can face barriers to accessing prevention, testing and care, says a new campaign.
News FDA sets June date for Gilead's twice-yearly HIV PrEP Gilead's already dominant position in HIV PrEP could be extended if the FDA approves a new twice-yearly injectable product later this year.
Patients Gilead's HIV success and controversy: Expanding access amid ... Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly effective medicine.
News Gilead, MSD say HIV combo could be weekly, oral HIV drug In a phase 2 trial, an antiretroviral combination developed by Gilead Sciences and MSD suppressed HIV with a single weekly oral dose, raising the hope of a new treatment option for patients
